6 news items
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
REPL
7 Jun 24
HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
REPL
23 May 24
-) and GM-CSF to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
REPL
16 May 24
protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
REPL
7 Apr 24
death and the activation of a systemic anti-tumor immune response. About Replimune Replimune Group
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REPL
4 Apr 24
death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity
pgjmhwvx1fcnzy9rs nmw1t
REPL
26 Mar 24
immunotherapies. Replimune's proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction
- Prev
- 1
- Next